Harvoni - Hepatitis C Treatment Tablet
From Medicines - Liver Disease
Ledipasvir 90 mg/sofosbuvir 400 mg. Harvoni® is indicated for the treatment of adults and pediatric patients ≥3 years with chronic hepatitis C virus (HCV) genotype 1, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis. HARVONI is used with ribavirin in GT 1 patients with decompensated cirrhosis and in GT 1 or 4 liver transplant recipients without cirrhosis or with compensated cirrhosis.
-
Most popular related searches
Product Details
Hepatitis B virus reactivation: Before starting treatment with HARVONI, your healthcare provider will do blood tests to check for hepatitis B virus infection. If you have ever had hepatitis B virus infection, the hepatitis B virus could become active again during or after treatment of hepatitis C virus with HARVONI. Hepatitis B virus becoming activeagain (called reactivation) may cause serious liver problems including liver failure and death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop taking HARVONI
Customer reviews
No reviews were found for Harvoni - Hepatitis C Treatment Tablet. Be the first to review!